Skip to main content
. Author manuscript; available in PMC: 2016 Feb 25.
Published in final edited form as: Osteoporos Int. 2015 Mar 20;26(6):1857–1864. doi: 10.1007/s00198-015-3100-7

Table 3.

Adverse Events

Adverse Event Risedronate

N (%)
Placebo

N (%)
P-value
Breast related 5 (9) 4 (7) 1.00
Gastrointestinal 4 (7) 13 (24) 0.019
Cardiovascular 8 (14) 11 (20) 0.459
Respiratory 4(7) 10(18) 0.093
Musculoskeletal 27 (49) 33 (61) 0.250
Serious 10 (18) 16 (30) 0.183
Nonserious 52(95) 50(93) 0.716